[go: up one dir, main page]

WO2019128999A1 - Procédé d'obtention de cellules car-t à taux positif élevé - Google Patents

Procédé d'obtention de cellules car-t à taux positif élevé Download PDF

Info

Publication number
WO2019128999A1
WO2019128999A1 PCT/CN2018/123561 CN2018123561W WO2019128999A1 WO 2019128999 A1 WO2019128999 A1 WO 2019128999A1 CN 2018123561 W CN2018123561 W CN 2018123561W WO 2019128999 A1 WO2019128999 A1 WO 2019128999A1
Authority
WO
WIPO (PCT)
Prior art keywords
car
antigen
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/123561
Other languages
English (en)
Chinese (zh)
Inventor
钱其军
金华君
江芏青
何周
孙艳
李林芳
师传胤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Cell Therapy Research Institute
Shanghai Cell Therapy Group Co Ltd
Original Assignee
Shanghai Cell Therapy Research Institute
Shanghai Cell Therapy Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Cell Therapy Research Institute, Shanghai Cell Therapy Group Co Ltd filed Critical Shanghai Cell Therapy Research Institute
Publication of WO2019128999A1 publication Critical patent/WO2019128999A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Definitions

  • the present invention relates to a method of obtaining high positive rate CAR-T cells.
  • Cancer has become the number one killer of human health.
  • the fast pace of life, huge work pressure, unhealthy eating habits, and poor environment are all accomplices of cancer, making cancer's high incidence and rejuvenation trend more and more obvious.
  • the commonly used treatments are very limited, and it is still necessary to explore a more effective treatment to improve the survival rate and quality of life of cancer patients.
  • chimeric antigen receptor T cell therapy has achieved very good curative effect in malignant hematological tumors, and the complete remission rate of relapsed and refractory B cell leukemia is over 90%.
  • CAR-T cell Novartis's tissue lecleucel chimeric antigen receptor T cell
  • ALL acute lymphoblastic leukemia
  • CAR-T drug Novartis's tissue lecleucel chimeric antigen receptor T cell
  • Yescarta for the treatment of adult patients with certain types of large B-cell lymphoma.
  • the approval of CAR-T drugs has taken CAR-T treatment to a new level.
  • a chimeric antigen receptor is a synthetic receptor that typically comprises an extracellular antigen binding domain, a transmembrane hinge region, and an intracellular signal transduction region.
  • scFv single-chain fragment variable
  • TAA antibody-associated antigen
  • ITAM immunoreceptor tyrosine-based activation Motifs
  • the overall efficacy of current CAR-T cell therapy is still not satisfactory, especially for solid tumors.
  • the transfection efficiency is low, and it is difficult to obtain a high positive rate of CAR-T cells, which is an important reason.
  • the transfection efficiency is difficult to break through 50%, usually only about 20%. It is generally necessary to ensure a sufficient amount of CAR-T positive cells by preparing a large number of cells.
  • T cells are transfected with the CAR gene by CD3/CD28 antibody coating or CD3/CD28 antibody magnetic beads to stimulate T cell activation, but this stimulation method is broad-spectrum for T cells, whether transfected or not.
  • the CAR gene will be activated. Due to competitive growth, the proportion of CAR-T cells may be continuously diluted, and the proportion of CAR-T in the resulting T cell population is very low.
  • T cells transfected with the CAR gene by using specific antigens.
  • the method uses the binding of specific antigens to scFv as the first signal for T cell activation and transduces the signal to CAR.
  • the T cell intracellular co-stimulation region activates the second signal to activate T cells, so that although a highly positive proportion of CAR-T cells can be obtained, the proliferation is slow and it is difficult to obtain a large number of target cells. The reason may be due to the T cell clustering effect.
  • the present invention provides a method of producing a CAR-T cell, the method comprising the step of incubating the CAR-T cell with a CD28 antibody and a chimeric antigen receptor-targeted antigen expressed by the CAR-T cell.
  • the antigen is an antigen specifically bound by a single chain antibody of a CAR expressed by the CAR-T cell.
  • the ratio of the antigen to the CD28 antibody is from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1.
  • the CAR targets mesothelin, EGFR, Her2, CD19 or mucin.
  • the antigen is mesothelin, EGFR, Her2, CD19 or mucin.
  • the CAR-T cells are transfected with a non-viral vector expressing the CAR.
  • the method comprises:
  • T cells were incubated with the CD28 antibody and the CAR-targeted antigen 4 to 8 hours after transfection.
  • the stimulatory factor IL-2 is also added upon incubation.
  • the present invention also provides a composition for producing CAR-T cells, which comprises a CD28 antibody and a chimeric antigen receptor-targeted antigen expressed by a CAR-T cell to be prepared.
  • the antigen is an antigen specifically bound by a single chain antibody of a CAR expressed by a CAR-T cell to be prepared.
  • the ratio of the antigen to CD28 antibody in the composition is from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1.
  • the antigen is mesothelin, EGFR, Her2, CD19 or mucin.
  • the concentration of the CD28 antibody in the composition is from 2 to 8 ug/ml and the concentration of the antigen is from 1 to 10 ug/ml.
  • the composition further comprises IL-2, preferably, the IL-2 is present in the composition at a level of from 50 to 1000 U/ml.
  • the invention also provides a kit comprising a CD28 antibody and an antigen targeted by a chimeric antigen receptor expressed by a CAR-T cell to be prepared.
  • the kit further comprises IL-2.
  • the kit further comprises a vector that integrates the chimeric antigen receptor expression cassette into the host cell genome.
  • the vector is a transposon vector, preferably, the transposon vector is a eukaryotic expression comprising a transposable element selected from the group consisting of piggybac, sleeping beauty, frog prince, Tn5 or Ty Carrier.
  • the vector is a cassette for expression of a chimeric antigen receptor between 5' LTR and 3' LTR, including a promoter sequence, a coding sequence for a chimeric antigen receptor, and a polyA tailing signal sequence.
  • the kit further contains a transfection reagent and/or instrument.
  • the invention also provides the use of a combination of a CD28 antibody and an antigen for promoting CAR-T cell proliferation, wherein the antigen is an antigen targeted by a chimeric antigen receptor expressed by the CAR-T cell.
  • the ratio of the antigen to the CD28 antibody is from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1.
  • the antigen is mesothelin, EGFR, Her2, CD19 or mucin.
  • Figure 1 Schematic diagram of the structure of the CAR gene.
  • FIG. 2 PBMC was transfected with meso3CAR gene by electroporation, and the positive rates of CAR-T were compared under the stimulation of antiCD3/antiCD28 and mesothelin/antiCD28, respectively.
  • FIG. 3 CAR-T cell positive rate under specific conditions of specific antigen and CD28 antibody.
  • FIG. 4A RTCA detects the killing of tumor cells by meso3CAR T cells with different positive rates.
  • Figure 4B Statistics on killing rates of tumor cells by meso3CAR T cells with different positive rates.
  • Figure 5 Flow-through detection of meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR, Her2-CAR five CAR-T ratios of positive cells stimulated by antiCD3/antiCD28 and corresponding antigen/antiCD28.
  • FIG. 6A-6B Proportion of memory T populations in five CAR-T cells of meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR, and Her2-CAR prepared by combining specific antigen with CD28 antibody.
  • Tem is an effector memory T cell
  • Tcm is a central memory T cell
  • Tm is a total memory T cell, that is, the sum of Tem and Tcm.
  • Figure 7 Proliferation of five kinds of CAR-T cells of meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR, and Her2-CAR in combination with specific antigen and CD28 antibody and preparation of specific antigen alone.
  • the inventors have established a mature preparation method for obtaining high positive rate CAR-T cells through a large amount of experiments and creative labor, and achieved more effective killing of tumor cell lines.
  • the present invention prepares CAR-T cells by a combination of a specific antigen and a CD28 antibody, initially obtaining a medium-positive proportion of CAR-T cells, contributing to their proliferation, and due to memory of specific antigens, the population The proportion of CAR-T cells in the process will be higher and higher, and finally a large number of high-positive CAR-T cells will be obtained.
  • expression cassette refers to the entire element required for expression of a gene, including a promoter, a gene coding sequence, and a PolyA tailing signal sequence.
  • coding sequence is defined herein as a portion of a nucleic acid sequence that directly determines the amino acid sequence of its protein product (eg, CAR, single chain antibody, hinge region, and transmembrane region).
  • the boundaries of the coding sequence are typically determined by a ribosome binding site (for prokaryotic cells) immediately upstream of the open reading frame of the 5' end of the mRNA and a transcription termination sequence immediately downstream of the open reading frame of the 3' end of the mRNA.
  • a coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.
  • Fc fragment crystallizable (Fc) of an antibody
  • Fc fragment crystallizable
  • costimulatory molecule refers to a molecule that is present on the surface of an antigen presenting cell and that binds to a costimulatory molecule receptor on a Th cell to produce a costimulatory signal.
  • the proliferation of lymphocytes requires not only the binding of antigens, but also the signals of costimulatory molecules.
  • the costimulatory signal is transmitted to the T cells mainly by binding to the co-stimulatory molecule CD80 on the surface of the antigen presenting cells, and CD86 binds to the CD28 molecule on the surface of the T cell.
  • B cells receive a costimulatory signal that can pass through a common pathogen component such as LPS, or through a complement component, or through activated antigen-specific Th cell surface CD40L.
  • linker or hinge is a polypeptide fragment that links between different proteins or polypeptides for the purpose of maintaining the spatial conformation of the linked protein or polypeptide to maintain the function or activity of the protein or polypeptide.
  • exemplary linkers include linkers containing G and/or S, as well as, for example, Furin 2A peptide.
  • an antibody that specifically binds to an antigen means that the antibody is less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, Affinity (KD) of 10 -8 M, 10 -9 M or 10 -10 M or less binds to the antigen.
  • KD Affinity
  • pharmaceutically acceptable excipient refers to carriers and/or excipients that are compatible pharmacologically and/or physiologically to the subject and active ingredient, which are well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers.
  • pH adjusting agents include, but are not limited to, phosphate buffers
  • surfactants include, but are not limited to, cationic, anionic or nonionic surfactants such as Tween-80
  • ionic strength enhancers include, but are not limited to, sodium chloride.
  • the term "effective amount” refers to a dose that can achieve a treatment, prevention, alleviation, and/or alleviation of a disease or condition described herein in a subject.
  • disease and/or condition refers to a physical state of the subject that is associated with the disease and/or condition described herein.
  • subject or “patient” may refer to a patient or other animal that receives the pharmaceutical composition of the invention to treat, prevent, ameliorate and/or alleviate the disease or condition of the invention, particularly a mammal, such as a human, a dog. , monkeys, cattle, horses, etc.
  • CAR chimeric antigen receptor
  • T cells immune cells
  • CAR typically comprises, in turn, an optional signal peptide, a polypeptide that binds to a tumor cell membrane antigen, such as a single chain antibody, a hinge region, a transmembrane region, and an intracellular signaling region.
  • a polypeptide that binds to a tumor cell membrane antigen is capable of binding to a membrane antigen that is widely expressed by tumor cells with moderate affinity.
  • the polypeptide that binds to the tumor cell membrane antigen may be a natural polypeptide or a synthetic polypeptide; preferably, the synthetic polypeptide is a single chain antibody or a Fab fragment.
  • single-chain antibody refers to an antibody fragment which is obtained by hinge-ligating an amino acid sequence of an antibody light chain variable region (VL region) and a heavy chain variable region (VH region), and having antigen-binding ability.
  • the single chain antibody of interest is from an antibody of interest.
  • Antibodies of interest may be human antibodies, including human murine chimeric antibodies and humanized antibodies. The antibody can be secreted or membrane anchored.
  • Antigen generally refers to a substance that induces an immune response.
  • An antigen herein refers in particular to an antigen to which a chimeric antigen receptor is targeted, particularly an antigen that specifically binds to a single chain antibody in a chimeric antigen receptor.
  • the present invention provides a method of producing a CAR-T cell, the method comprising the step of incubating the CAR-T cell with a CD28 antibody and a chimeric antigen receptor-targeted antigen expressed by the CAR-T cell.
  • the CD28 antibody is a CD28 antibody well known in the art, especially a CD28 antibody commonly used in the proliferation culture of CAR-T cells in the art.
  • the antigens used for incubation are different for different CAR-T cells.
  • the antigen should be an antigen targeted by the CAR expressed by the CAR-T cell, especially an antigen to which the single-chain antibody in the CAR can specifically bind.
  • the chimeric antigen receptor of interest may be directed against one or more of the following antigens: Her2, CD19, CD20, CEA, GD2 (also known as B4GALNT1, ⁇ 1,4-acetyl-galactosyltransferase) 1), FR (Flavin reductase), PSMA (prostate specific membrane antigen), PMEL (premelanomeric protein), CA9 (carbonic anhydrase IX), CD171/L1-CAM, IL-13R ⁇ 2, MART-1 (also known as mucin-A), ERBB2, NY-ESO-1 (also known as CTAG1B, cancer/testis antigen 1B), MAGE (melanoma-associated antigen E1) family protein, BAGE (B melanoma antigen family) family Protein, GAGE (growth hormone releasing factor) family protein, AFP ( ⁇ -fetoprotein), MUC1 (mucin 1, cell surface related), CD22, CD23, CD30, CD33, CD44v7
  • the chimeric antigen receptor of interest is a chimeric antigen receptor directed against Her2, CD19, EGFR, mesothelin or mucin (Muc1). It will be understood that unless otherwise indicated, the various antigens described herein are well known in the art and the sequences are well known in the art.
  • an antigen suitable for use in the present invention may be a specific antibody (eg, a single chain antibody, scFv) that can be used to construct a chimeric antigen receptor to prepare a corresponding CAR-T cell antigen, including but not limited to the foregoing.
  • Antigens include, inter alia, Her2, CD19, EGFR, mesothelin and Muc1.
  • CAR-T cells can be incubated with the CD28 antibody and the corresponding antigen.
  • CAR-T cells can be constructed first, and then the constructed CAR-T cells are incubated with the CD28 antibody and the corresponding antigen.
  • the methods of the invention for preparing CAR-T cells further comprise the step of constructing CAR-T cells.
  • CAR-T cells can be prepared using methods routine in the art, including transfection of suitable T cells using a suitable recombinant plasmid.
  • the coding sequence of the chimeric antigen receptor is usually contained in the recombinant plasmid.
  • CARs suitable for use in the present invention typically contain an optional signal peptide sequence, an amino acid sequence that specifically recognizes the antigen, a hinge region, a transmembrane region, an intracellular costimulatory signal domain, and an intracellular signal domain.
  • a signal peptide is a short peptide chain (5-30 amino acids in length) that directs the transfer of newly synthesized proteins to the secretory pathway, often referred to as the N-terminal amino acid sequence in the newly synthesized polypeptide chain that directs transmembrane transfer (localization) of the protein. (Sometimes not necessarily at the N-terminus), it is responsible for directing proteins into subcellular organelles with different membrane structures.
  • the signal peptide can be a secreted signal peptide or a membrane-bound signal peptide. Suitable signal peptides include CD8 signal peptides, CD28 signal peptides or CD4 signal peptides and light chain signal peptides.
  • the amino acid sequence of an exemplary CD8 signal peptide can be as shown in amino acid residues 1-22 of SEQ ID NO: 1, or as shown in amino acid residues 1 to 21 of SEQ ID NO: 7, the coding sequence of which is preferably as The nucleotide sequence of positions 1-66 of SEQ ID NO: 2 or the nucleotide sequence of positions 1-63 of SEQ ID NO: 8 is shown.
  • the amino acid sequence that specifically recognizes an antigen in a chimeric antigen receptor is typically an antibody, particularly a single chain antibody.
  • Single chain antibodies directed against an antigen can be prepared using techniques well known in the art.
  • a single chain antibody in a chimeric receptor antigen can be selected from a single chain antibody directed against any of the antigens described above, particularly a single strand directed against Her2, CD19, EGFR, mesothelin or Mucl antibody.
  • the amino acid sequence of a single chain antibody directed against mesothelin is as shown in amino acid residues 23-272 of SEQ ID NO: 1; the amino acid sequence of a single chain antibody directed against EGFR is set forth in SEQ ID NO: 3
  • the amino acid sequence of the single-chain antibody against Her2 is shown in amino acid residues 23-264 of SEQ ID NO: 5; the amino acid sequence of the single-chain antibody against CD19 is SEQ ID NO :7 indicates the amino acid residues at positions 22-263; the amino acid sequence of the single-chain antibody against mucin is as shown in amino acid residues 23-269 of SEQ ID NO: 9.
  • the corresponding coding sequences for these single chain antibodies can be found in the corresponding portions of SEQ ID NOs: 2, 4, 6, 8, and 10, respectively.
  • the hinge region refers to the region between the functional regions of the immunoglobulin heavy chain CH1 and CH2, which is rich in proline, does not form an alpha helix, is prone to stretching and is somewhat distorted, and is beneficial to the antigen binding site and antigenic epitope of the antibody. Complementary complementarity.
  • a suitable hinge region may be selected from any one or more of the extracellular hinge region of CD8, the IgG1 Fc CH2CH3 hinge region, the IgD hinge region, the extracellular hinge region of CD28, the IgG4 Fc CH2CH3 hinge region, and the extracellular hinge region of CD4. .
  • the hinge region is preferably a hinge region that is longer than 50 amino acid residues, more preferably 80 amino acids or longer.
  • the amino acid sequence of the exemplary IgG4 FcCH2CH3 hinge region is shown in amino acid residues 273-500 of SEQ ID NO: 1, and the coding sequence thereof is preferably as shown in SEQ ID NO: 2, bases 817-1500.
  • the amino acid sequence of the exemplary CD8 alpha hinge region is set forth in amino acid residues 264 to 318 of SEQ ID NO: 3, and the coding sequence thereof is preferably shown in nucleotide sequence 789-954 of SEQ ID NO: 4.
  • the transmembrane region may be one of a CD28 transmembrane region, a CD8 transmembrane region, a CD3 ⁇ transmembrane region, a CD134 transmembrane region, a CD137 transmembrane region, an ICOS transmembrane region, and a DAP10 transmembrane region.
  • the amino acid sequence of the exemplary CD28 transmembrane region is set forth in SEQ ID NO: 1 at 501-528, and the coding sequence thereof is preferably shown as bases 1501-1584 of SEQ ID NO: 2.
  • the amino acid sequence of the exemplary CD8 transmembrane region is shown in amino acid residues 319 to 344 of SEQ ID NO: 3, and the coding sequence thereof is preferably shown in nucleotide sequence 955-1032 of SEQ ID NO: 4.
  • the intracellular co-stimulatory signal domain including the intracellular domain of the costimulatory signaling molecule may be selected from the group consisting of CD28, CD134/OX40, CD137/4-1BB, lymphocyte-specific protein tyrosine kinase (LCK), and inducible T cell costimulation.
  • Intracellular domain of factor (ICOS) and DNAX activator protein 10 (DAP10) are selected from the group consisting of CD28, CD134/OX40, CD137/4-1BB, lymphocyte-specific protein tyrosine kinase (LCK), and inducible T cell costimulation.
  • Intracellular domain of factor (ICOS) and DNAX activator protein 10 (DAP10) Intracellular domain of factor (ICOS) and DNAX activator protein 10 (DAP10).
  • the amino acid sequence of the exemplary intracellular domain of CD28 is shown in amino acid residues 529-569 of SEQ ID NO: 1, and the exemplary coding sequence is shown in bases 1585-1707 of SEQ ID NO
  • the intracellular signal domain is preferably an immunoreceptor tyrosine activation motif, which may be a CD3 sputum intracellular signal domain or an Fc ⁇ RI gamma intracellular signal domain.
  • the amino acid sequence of the exemplary CD3 sputum intracellular signal domain is set forth in amino acid residues 570-681 of SEQ ID NO: 1, and exemplary coding sequences thereof are set forth in SEQ ID NO: 2, 1708-2043.
  • a chimeric antigen receptor such as a signal peptide, a light chain variable region and a heavy chain variable region, a hinge region, a transmembrane region, an intracellular costimulatory signal domain, and an intracellular signal domain of a single chain antibody
  • the linker sequence can be a linker sequence suitable for use in antibodies well known in the art, such as linker sequences comprising G and S.
  • the linker may be 3 to 25 amino acid residues in length, for example 3 to 15, 5 to 15, and 10 to 20 amino acid residues.
  • the linker sequence is a polyglycine linker sequence.
  • the amount of glycine in the linker sequence is not particularly limited, but is usually 2 to 20, for example, 2 to 15, 2 to 10, and 2 to 8.
  • the linker may also contain other known amino acid residues such as alanine (A), leucine (L), threonine (T), glutamic acid (E), styrene Amino acid (F), arginine (R), glutamine (Q), and the like.
  • the coding sequence of the chimeric antigen receptor can be obtained by PCR amplification.
  • primers can be designed according to the target sequence, and the relevant sequences can be amplified by using a commercially available cDNA library or a cDNA library prepared by a conventional method known to those skilled in the art as a template.
  • a template a commercially available cDNA library or a cDNA library prepared by a conventional method known to those skilled in the art as a template.
  • the coding sequences for exemplary chimeric antigen receptors are set forth in SEQ ID NOs: 2, 4, 6, 8, and 10.
  • the vector contains the corresponding promoter sequence and the polyA tailing signal sequence. If these sequences are not included in the vector, these sequences can be ligated to the coding sequence of the chimeric antigen receptor using methods routine in the art.
  • a preferred vector is a non-viral vector, more preferably a vector (also referred to as an integration vector) that integrates the expression cassette of the chimeric antigen receptor into the genome of the host cell, particularly a transposon vector.
  • the transposon vector is a eukaryotic expression vector comprising a transposable element selected from the group consisting of piggybac, sleeping beauty, frog prince, Tn5 or Ty.
  • Such transposon vectors contain the 5' inverted terminal repeat (5' LTR) of the corresponding transposon and the 3' inverted terminal repeat (3' LTR) of the corresponding transposon.
  • the transposase can be a transposase from a piggybac, sleeping beauty, frog prince, Tn5 or Ty transposition system.
  • sequences of the 5'LTR and 3'LTR in the vector are also correspondingly changed to sequences adapted to the transposition system, which can be readily determined by those skilled in the art.
  • LTR is the expression cassette for the CAR, including the corresponding promoter sequence, the coding sequence for the CAR, and the polyA tailing signal sequence.
  • the transposase is a transposase from a piggybac transposition system.
  • the 5' inverted terminal repeat and the 3' inverted terminal repeat of the transposon are the 5' inverted terminal repeat and the 3' inverted terminal repeat of the piggybac transposon, respectively.
  • the transposon 5' inverted terminal repeat is SEQ ID NO: 1 as described in CN 201510638974.7, the disclosure of which is incorporated herein by reference.
  • the transposon 3' inverted terminal repeat is as set forth in CN 201510638974.7 SEQ ID NO:4.
  • the piggybac transposase is a transposase comprising a c-myc nuclear localization signal coding sequence.
  • the coding sequence for the piggybac transposase is as shown in CN 201510638974.7 SEQ ID NO: 5.
  • the promoter of the transposase coding sequence can be a variety of promoters known in the art for controlling expression of the transposase coding sequence.
  • the expression of the transposase coding sequence is controlled using a CMV promoter.
  • the sequence of the CMV promoter can be as shown in CN 201510638974.7 SEQ ID NO: 6.
  • a recombinant plasmid containing a coding sequence for a chimeric antigen receptor is constructed using the pNB328 vector disclosed in CN 201510638974.7 as a backbone vector.
  • transfection can be carried out by conventional transfection methods in the art, including but not limited to: viral transduction, microinjection, particle bombardment, gene gun transformation and electroporation.
  • the vector is transfected into a cell of interest using electroporation.
  • the cells of interest may be various T cells well known in the art including, but not limited to, peripheral blood T lymphocytes, cytotoxic killer T cells (CTLs), helper T cells, suppressor/regulatory T cells, ⁇ T cells, and cytokines.
  • T cells of mixed cell populations such as induced killer cells (CIK) and tumor infiltrating lymphocytes (TIL).
  • CIK induced killer cells
  • TIL tumor infiltrating lymphocytes
  • the T cell can be derived from a PBMC of a B cell malignancy patient.
  • the T cell is a primary cultured T cell.
  • the resulting cells are incubated with the CD28 and antigen of the present invention while the stimulating factor IL-2 is added.
  • the ratio of the antigen to the CD28 antibody is usually from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1 by mass.
  • the concentration of the CD28 antibody is from 2 to 8 ug/ml, such as 5 ug/ml; the concentration of the antigen is from 1 to 10 ug/ml, such as from 2.5 to 10 ug/ml, or from 5 to 10 ug/ml.
  • the concentration of IL-2 is usually from 50 to 1000 U/ml.
  • Incubation conditions are conventional incubation conditions, such as a 37 ° C, 5% CO 2 atmosphere.
  • a T cell mixture having a CAR-T cell positive rate of 50% or more can be obtained.
  • a T cell mixture having a CAR-T cell positive rate of greater than 80% can be obtained using the methods of the invention.
  • the present invention also provides a composition for producing CAR-T cells, which comprises a CD28 antibody and a chimeric antigen receptor-targeted antigen expressed by a CAR-T cell to be prepared.
  • the antigen is an antigen specifically bound by a single-chain antibody of a CAR expressed by a CAR-T cell to be prepared.
  • the antigen may be any of the antigens described above.
  • the antigen is mesothelin, EGFR, Her2, CD19 or mucin.
  • the ratio of the antigen to the CD28 antibody in the composition is from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1.
  • the concentration of the CD28 antibody in the composition is from 2 to 8 ug/ml and the concentration of the antigen is from 1 to 10 ug/ml.
  • the composition may also contain IL-2.
  • the IL-2 is present in the composition in an amount of from 50 to 1000 U/ml.
  • the composition may also contain a suitable solvent.
  • the solvent is PBS.
  • kits of the invention also provide a kit comprising a CD28 antibody and an antigen as described herein.
  • the CD28 antibody and antigen described in the kit may be packaged separately or in the form of a mixture.
  • the kits of the invention comprise a composition described herein.
  • the kit further comprises IL-2.
  • the kit may also contain a vector that integrates the chimeric antigen receptor expression cassette into the host cell genome.
  • the vector may be a vector described herein, preferably the vector is a transposon vector; more preferably, the transposon vector is a eukaryotic expression comprising a transposable element selected from the group consisting of piggybac, sleeping beauty, frog prince, Tn5 or Ty Carrier.
  • the vector is a blank vector.
  • a blank vector can be used by a person skilled in the art to construct a recombinant vector containing the coding sequence of the chimeric antigen receptor, and then the CD28 antibody and the corresponding antigen contained in the kit are used for preparation of the corresponding CAR-T cells.
  • the blank vector can be, for example, the pNB328 vector described herein or other vectors conventionally used in the art to construct CAR.
  • the kit may further contain a suitable reagent for constructing the recombinant vector using the blank vector.
  • the vector is a vector comprising a coding sequence for a CAR.
  • the antigen contained in the kit should be an antigen which can be specifically bound or recognized by the single-chain antibody of the CAR.
  • the kit may also contain transfection reagents and/or instruments.
  • the invention also provides the use of a combination of a CD28 antibody and an antigen described herein for promoting CAR-T cell proliferation.
  • the ratio of the antigen to the CD28 antibody is from 1:5 to 3:1, preferably from 1:2 to 2:1, more preferably 1:1 by mass.
  • the antigen is mesothelin, EGFR, Her2, CD19 or mucin.
  • the gene sequence of meso3CAR, EGFRCAR, HER2CAR, MUC1CAR and CD19CAR was synthesized by Shanghai Jierui Biotech Co., Ltd. as shown in SEQ ID NOs: 2, 4, 6, 8 and 10, respectively.
  • the structural pattern is shown in Figure 1, where mesoCAR
  • the hinge region of CD19CAR is the IgG4 CH2CH3 hinge region, and the hinge regions of the other three CARs are the CD8 alpha hinge region.
  • Example 2 Comparison of the positive rate of meso3CAR T cells prepared by antiCD3/antiCD28 and mesothelin/antiCD28
  • PBMCs Peripheral blood mononuclear cells
  • the PBMCs were cultured for 2-4 h, in which the unattached suspension cells were the initial T cells, and the suspension cells were collected into a 15 ml centrifuge tube, centrifuged at 1200 rmp for 3 min, and the supernatant was discarded.
  • Antibody or antigen coating method Add CD3 and CD28 antibody or mesothelin antigen and CD28 antibody to PBS at a concentration of 5 ug/ml, mix well, and add to the six-well plate in an amount of 1 ml per well, 4 Allow to stand overnight at °C or 37 ° C for 4 hours. Discard the liquid during use.
  • Detection of positive rate of CAR-T cells The positive rate of cell flow detection on the 7th and 15th day was collected. Specific methods of operation: Collect cells, 1 ⁇ 10 6 per tube, add 1 ug of primary anti-meso-Biotin (with biotin label on mesothelin antigen), and incubate at 4 ° C for 30 minutes. Wash twice with saline, add 1 ul of secondary anti-streptomycin-PE, and incubate for 30 minutes at 4 °C. Wash the saline twice, and check it on the machine. The secondary antibody was added as a negative control, and the results are shown in Fig. 2.
  • Example 4 Comparison of the killing effect of meso3CAR T cells with different positive rates on tumor cell lines
  • meso3CAR T cells with different positive rates on tumor cell lines was detected by real-time label-free cell function analyzer. Specifically, ovarian cancer cell line SKOV3 with high expression of mesothelin was selected as the target cell, and different positive rates were detected by using Essen's real-time label-free cell function analyzer (RTCA) (10%, 30%, 50%, 70). % and 90%, meso3CAR T cells with different positive rates can be adjusted by in vitro killing activity of meso3CAR T cells by adding Mock T cells transfected with pNB328 empty vector in high positive rate meso3CAR T cells. The specific steps are as follows:
  • Target cell plating ovarian cancer cell SKOV3 (purchased from the American Type Culture Collection ATCC) was placed in a plate containing the detection electrode at 10 4 cells/50 ⁇ l per well, and left for a few minutes until the cells were stabilized. Into the instrument, start step 2, culture the cells;
  • Example 5 Comparison of the positive rates of five kinds of CAR-T cells of meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR and Her2CAR prepared by antiCD3/antiCD28 and specific antigen/antiCD28
  • the plasmids used were pNB328-meso3CAR, pNB328-EGFR-CAR, pNB328-MUC1-CAR, pNB328-CD19CAR, pNB328-HER2-CAR to construct meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR, respectively.
  • Her2CAR five kinds of CAR-T cells.
  • the corresponding CAR-T was cultured and amplified with antiCD3/antiCD28 and specific antigen/antiCD28, respectively, and the amplification method was the same as that described in Example 2.
  • the specific antigens were mesothelin antigen, EGFR, mucin, CD19 and Her2, the concentration of each antigen was 5 ug/ml, and the concentration of CD28 antibody was 5 ug/ml.
  • Various CAR-T cells were collected on the 15th day, and the positive rate was detected by flow, and the detection method was the same as that described in Example 2.
  • the primary antibodies used were meso-Biotin, EGFR-Biotin, MUCl-Biotin, CD19-Biotin, Her2-Biotin.
  • Example 6 Comparing the ratio of memory T cells in meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR, and Her2CAR five CAR-T cells prepared by antiCD3/antiCD28 and specific antigen/antiCD28
  • CAR-T cells of meso3CAR, EGFR-CAR, MUClCAR, CD19CAR, and Her2CAR were constructed as described in Example 2, and these five CAR-T cells were cultured and expanded as described in Example 5. On day 15, cells were harvested and the memory T ratio was detected by flow using CD45RO, CCR7 antibody.
  • CAR-T cells in the selective amplification system produced a higher proportion of memory T cells.
  • Example 7 Proliferation of five kinds of CAR-T cells of meso3CAR, EGFR-CAR, MUC1CAR, CD19CAR and Her2-CAR under the conditions of preparation of specific antigen combined with CD28 antibody and specific antigen alone
  • CAR-T cells Five kinds of CAR-T cells, meso3CAR, EGFR-CAR, MUClCAR, CD19CAR and Her2CAR, were constructed as described in Example 4.
  • the culture was carried out under the conditions of preparation of a specific antigen in combination with a CD28 antibody (concentration of 5 ug/ml) and a specific antigen alone (concentration: 10 ug/ml).
  • the initial cell amount was the same, and the number of cells on the 15th day was counted and counted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé d'obtention de cellules CAR-T à taux positif élevé, comprenant l'étape consistant à incuber des cellules CAR-T à l'aide d'un anticorps anti-CD28 et d'un antigène ciblé par un récepteur antigénique chimérique qui est exprimé par les cellules CAR-T. Grâce au procédé de la présente invention, un rapport modérément positif de cellules CAR-T peut être obtenu initialement, celui-ci aidant à la prolifération correspondante et, du fait de la mémoire concernant un antigène spécifique, le rapport des cellules CAR-T dans la population sera de plus en plus élevé, de telle sorte qu'un grand nombre de cellules CAR-T à un taux positif élevé sera finalement obtenu.
PCT/CN2018/123561 2017-12-28 2018-12-25 Procédé d'obtention de cellules car-t à taux positif élevé Ceased WO2019128999A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711459390.9A CN109971718B (zh) 2017-12-28 2017-12-28 获得高阳性率car-t细胞的方法
CN201711459390.9 2017-12-28

Publications (1)

Publication Number Publication Date
WO2019128999A1 true WO2019128999A1 (fr) 2019-07-04

Family

ID=67066650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/123561 Ceased WO2019128999A1 (fr) 2017-12-28 2018-12-25 Procédé d'obtention de cellules car-t à taux positif élevé

Country Status (2)

Country Link
CN (1) CN109971718B (fr)
WO (1) WO2019128999A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113403284A (zh) * 2021-06-28 2021-09-17 郑州大学 Plpp1在利用car-t技术防治实体瘤中的应用
CN113549598A (zh) * 2020-04-23 2021-10-26 上海细胞治疗集团有限公司 一种car-t细胞的制备方法
CN116785415A (zh) * 2023-05-04 2023-09-22 北京百普赛斯生物科技股份有限公司 一种特异性针对免疫细胞激活/增殖刺激的产品、制备及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119708251A (zh) * 2023-09-27 2025-03-28 北京大学 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105154473A (zh) * 2015-09-30 2015-12-16 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
WO2017061615A1 (fr) * 2015-10-08 2017-04-13 国立大学法人名古屋大学 Procédé de préparation de lymphocytes t génétiquement modifiés exprimant un récepteur antigénique chimérique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021118125A (ru) * 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
CN108473957B (zh) * 2015-04-17 2024-07-16 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105154473A (zh) * 2015-09-30 2015-12-16 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
WO2017061615A1 (fr) * 2015-10-08 2017-04-13 国立大学法人名古屋大学 Procédé de préparation de lymphocytes t génétiquement modifiés exprimant un récepteur antigénique chimérique

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549598A (zh) * 2020-04-23 2021-10-26 上海细胞治疗集团有限公司 一种car-t细胞的制备方法
CN113403284A (zh) * 2021-06-28 2021-09-17 郑州大学 Plpp1在利用car-t技术防治实体瘤中的应用
CN116785415A (zh) * 2023-05-04 2023-09-22 北京百普赛斯生物科技股份有限公司 一种特异性针对免疫细胞激活/增殖刺激的产品、制备及应用
CN116785415B (zh) * 2023-05-04 2024-03-22 北京百普赛斯生物科技股份有限公司 一种特异性针对免疫细胞激活/增殖刺激的产品、制备及应用

Also Published As

Publication number Publication date
CN109971718A (zh) 2019-07-05
CN109971718B (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
EP4083073B1 (fr) Nouveau récepteur antigénique chimérique et utilisation associée
JP7431171B2 (ja) 抗体修飾キメラ抗原受容体修飾ｔ細胞及びその使用
CN112469829B (zh) 包含抗gpc3单链抗体的car
WO2019149249A1 (fr) Récepteur antigénique chimérique (car) se liant à bcma et ses applications
WO2019149250A1 (fr) Récepteur antigénique chimérique (car) se liant à bcma et ses applications
CN109971712B (zh) 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN112566698A (zh) T细胞受体和表达该t细胞受体的工程化细胞
WO2019020088A1 (fr) Lymphocyte t modifié par un récepteur antigénique chimérique ciblant la mésothéline et son utilisation
CN114891751A (zh) 一种高效稳定表达激活型抗体的car-t细胞及其用途
WO2019129146A1 (fr) Cellule car-t spécifique de l'egfr capable de sécrétion autocrine de l'anticorps cd47 et application de la cellule car-t
CN116003628A (zh) 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2019128999A1 (fr) Procédé d'obtention de cellules car-t à taux positif élevé
KR20220018479A (ko) 동종이계 car-t 세포, 이의 제조 및 응용
WO2019128994A1 (fr) Cellule t car spécifique de muc1 exprimant de façon stable un anticorps pd-1, et son utilisation
WO2019128998A1 (fr) Anticorps pd-1 à auto-expression, lymphocytes t modifiés par récepteur antigénique chimérique ciblant la mésothéline, et utilisation correspondante
WO2017219933A1 (fr) Lymphocyte t permettant l'expression efficace et stable d'un anticorps et application associée
WO2019129174A1 (fr) Cellule car-t ciblant le cd19 et exprimant un anticorps cd40 à un niveau élevé de stabilité, et son utilisation
JP2021509290A (ja) 双方向活性化共刺激分子受容体及びその用途
CN113528452B (zh) 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
WO2019129124A1 (fr) Lymphocyte t contenant un anticorps anti-cd40 et un gène récepteur d'antigène chimère spécifique à muc1 et utilisation correspondante
WO2019129090A1 (fr) Molécule/récepteur de costimulation à activation bidirectionnelle cd28 et utilisations associées
CN111378046B (zh) 一种免疫效应细胞转换受体
WO2019129138A1 (fr) Lymphocytes car-t ciblant la famille des récepteurs erbb et auto-exprimant un anticorps pd-1 et leur utilisation
WO2019128996A1 (fr) Lymphocyte t-car spécifique de la mésothéline exprimant un anticorps cd47, et son utilisation
WO2019129056A1 (fr) Récepteur de molécule costimulatrice à activation bidirectionnelle cd137 et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18893794

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18893794

Country of ref document: EP

Kind code of ref document: A1